Pharmacists using HAPPI software to make birth control easier to get
Official title: HAPPI (Hormonal Contraception Access Through Pharmacist Prescribing Implementation): Phase 2 (Aim 1)
Run by Empowerx INC · NCT06823037 · Data updated 2026-11-12
This project will test whether the HAPPI software helps pharmacists provide birth control more easily and helps patients access birth control at participating pharmacies.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 150 (estimated) |
| Sponsor | Empowerx INC Academic / other |
| Locations | 1 site (Del Mar, California) |
| Status | Recruiting |
| Started | October 9, 2025 |
| Main results expected | August 31, 2026 |
| Study ends | August 31, 2026 |
| Registry record updated | December 4, 2025 |
| Trial ID | NCT06823037 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 18 or older who seek pharmacist-prescribed birth control at a participating pharmacy and are willing to use the HAPPI software.
✕Probably not a fit
People under 18, those who cannot or will not use the software, or those living outside areas with participating pharmacies may not benefit from this intervention.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
Researchers will compare how pharmacists implement and how patients access pharmacist-provided birth control services with and without the HAPPI software to determine whether the technology improves implementation and access. The trial enrolls pharmacists who will use HAPPI while delivering routine birth control services and patients aged 18 and older who seek contraception at participating pharmacies. Primary outcomes include measures of ease of pharmacist workflow and patient access to contraception. The lead sponsor is EmPowerX Inc with collaboration from Purdue University, and activities are being conducted at participating EmpoweRx locations in Del Mar, California.
Why it matters
Potential benefit: If successful, HAPPI could shorten wait times and simplify the process of getting birth control from pharmacies, improving timely access for patients.
How similar studies have gone: Previous programs enabling pharmacist prescribing of contraception have improved access in some regions, though digital implementation tools like HAPPI have been less widely tested.
Who can join: the full rules
Show full inclusion / exclusion criteria
PHARMACIST Participants Inclusion Criteria: * 18 years of age or older * Provide birth control services in a participating pharmacy * Use the HAPPI software to provide birth control services Exclusion Criteria: * None PATIENT Participants Inclusion Criteria: * 18 years of age or older * Seek birth control services at a participating pharmacy * Use the HAPPI software to receive birth control services at a participating pharmacy Exclusion Criteria: * NONE
Where it's running
-
EmpoweRx, Inc
Del Mar, California, United States Recruiting
Study contacts
- Study coordinator: Jenny L Newlon, PharmD, PhD
- Email: jenny@birthcontrolpharmacist.com
- Phone: 8584120984
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Pharmacist-guided PEP/PrEP Access Using PEPPI Software
This trial tests whether the PEPPI software helps pharmacists provide PEP/PrEP and helps patients access these HIV prevention options.
-
Effectiveness of the Natural Cycles birth control app
This study will test how well the Natural Cycles app prevents pregnancy over one year in sexually active women aged 18 to 35 with no known infertility.
-
Female Reproductive Health in the Canadian Armed Forces: Understanding Issues from Contraception to Pelvic Floor Dysfunction
This observational study looks at reproductive health among women in the Canadian Armed Forces to see how contraception, pregnancy outcomes, infertility, pelvic floor issues, and related factors affect service members and veterans.
-
Long-acting HIV PrEP and contraception PK study in AGYW
This study tests how long-acting cabotegravir for PrEP interacts with hormonal contraception in young women.
-
Vasectomy: Right for Me? — a web-based decision aid
A web-based decision aid helps men think clearly about vasectomy and other birth control options to see if it fits their goals.
-
Contraceptive patch designed to stop ovulation
This trial tests whether a norelgestromin transdermal patch can keep ovulation suppressed for 84 days even when users make intentional application mistakes, in healthy women aged 18–35.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.